Tradjenta Receives Approval in Europe
Updated: 8/14/21 11:00 amPublished: 9/30/11
In late August, the European Commission approved Boehringer Ingelheim/Eli Lilly’s DPP-4 inhibitor, Tradjenta, for type 2 diabetes. Tradjenta (also known as Trajenta in the EU) is a member of the same class of drugs as Januvia, Galvus (EU only) and Onglyza. As a reminder, the drug was approved in June in the US (for more information, see NewNowNext in diaTribe #33). Tradjenta is unique in that it comes in only one dose and does not require dose adjustment for those with impaired kidney function. Given that approximately 50% of people with type 2 diabetes have some form of chronic kidney disease, Tradjenta could make doctors and patients lives a little bit easier by eliminating dose confusion. --DZ/AB
